Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
Metrics to compare | ZELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZELAPeersSector | |
---|---|---|---|---|
P/E Ratio | −25.5x | −1.7x | −0.5x | |
PEG Ratio | 0.67 | −0.01 | 0.00 | |
Price/Book | 3.6x | 1.2x | 2.6x | |
Price / LTM Sales | 542.9x | 3.6x | 2.9x | |
Upside (Analyst Target) | 121.9% | 51.3% | 53.0% | |
Fair Value Upside | Unlock | 9.7% | 8.9% | Unlock |